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USP <795>, <797>, and <800>
On June 1, 2019, the United States Pharmacopeial 
Convention (USP) published revisions to USP Chapters 
<795> and <797>, which were slated to become effective 
on December 1, 2019. USP also announced that USP 
Chapter <800> would become effective on December 
1, 2019. Consequently, the Iowa Board of  Pharmacy 
amended Iowa Administrative Code (IAC) 657 – 8.5(11) 
to require compliance with USP Chapter <800> effective 
December  1, 2019. 
On September 23, 2019, USP announced that the effective 
date of the  published revisions to USP Chapters <795> and 
<797> would be delayed, no longer becoming effective on 
December 1, 2019. USP maintained the December 1, 2019 
effective date for USP Chapter <800>.
USP is considering the following appeal topics for USP 
Chapters <795> and <797>: 
1. beyond-use date provisions in both chapters
2. removal of the alternative technology provision 
from USP Chapter <797> 
3. the applicability of both chapters to veterinary 
practitioners
The Board recognizes that if USP’s appointed appeals 
panel approves one or more appeals, the USP Expert Com-
mittee’s review of USP Chapters <795> and <797> is not 
necessarily limited to the sections under appeal. In accor-
dance with Rules 657 – 20.3 and 657 – 20.4, the proposed 
revisions will become effective, and enforceable by the 
Board, on the effective date established by USP. 
The Board has received several inquiries as to how the 
Board intends to enforce USP Chapters <795>, <797>, 
and <800> in light of USP’s recent announcement. On 
October 3, 2019, the Board convened and made the 
following decisions regarding enforcement.
Enforcement of USP Chapter <800>
All pharmacies are expected to be fully compliant with 
USP Chapter <800> beginning on December 1, 2019. This 
includes pharmacies that receive, store, handle, dispense, 
or compound hazardous drugs.
USP Chapters <795> and <797>: Current 
Versions Versus Proposed Revisions
 ♦ A pharmacy that has made progress toward comply-
ing with the proposed revisions to USP Chapters 
<795> and <797> will not be penalized for doing so. 
A pharmacy that is already compliant or making prog-
ress toward compliance with the proposed revisions 
will have a head start at achieving compliance by the 
new effective date, which will be established by USP.
 ♦ During this period of flux, a pharmacy may comply 
with either the current versions or the proposed revi-
sions of  USP Chapters <795> and <797>. A pharmacy 
is expected to establish and follow standard operating 
procedures for sterile and nonsterile compounding 
that identify the version of USP Chapter <795> or 
<797> it intends to follow. Requirements specified by 
USP Chapter <800> must be followed for hazardous 
compounding even if not specified by current versions 
of USP Chapters <795> and <797>, unless a delayed 
compliance petition has been granted. 
 ♦ All compounding pharmacies will be expected to 
comply with the proposed revisions to USP Chapters 
<795> and <797> by the effective date established by 
USP, which has yet to be determined.
Delayed Compliance Petitions
 ♦ Board Rule 657 – 8.5(11) establishes a process where-
by a pharmacy engaged in compounding of hazardous 
drugs may request delayed compliance for specific 
requirements of USP Chapter <800> pertaining to 
compounding in accordance with Rule 657 – 20.5. The 
Board has received and responded to several petitions 
filed under these provisions.
 ♦ A compounding pharmacy that can comply with all 
requirements of USP Chapter <800> by December 1, 
agency states. “But compounded drugs are not approved 
by the FDA and, therefore, have not been evaluated for 
safety, efficacy or quality. We’ve seen first-hand the harm 
they can cause patients when they’re not appropriately 
compounded.”
HHS, FDA Publish New Action Plan for 
Importation of Certain Prescription Drugs 
The US Department of Health and Human Services 
(HHS) and FDA have published a Safe Importation Ac-
tion Plan to allow for the safe importation of certain drugs 
originally intended for foreign markets. The action plan 
outlines two possible pathways: 
♦ Pathway 1 would rely on the authority in the Federal
Food, Drug, and Cosmetic Act Section 804 to authorize
demonstration projects to allow importation of drugs
from Canada. The proposed rules would include con-
ditions to ensure the importation poses no additional
risk to consumers and must result in a significant cost
reduction.
♦ Pathway 2 would allow manufacturers to import ver-
sions of FDA-approved drug products that they sell in
foreign countries that are the same as the US versions.
Manufacturers would use a new National Drug Code
for those products, potentially allowing them to of-
fer a lower price than what their current distribution
contracts require.
 The action plan states that the final proposal for these 
rules may differ from the descriptions “to reflect further 
consideration of the relevant issues.”
 “Today’s proposal is the result of the hard work by the 
dedicated staff of the FDA, in close collaboration with HHS 
and the White House, to identify potential pathways we can 
pursue to support the safe importation of certain prescription 
drugs,” said Acting FDA Commissioner Ned Sharpless, MD 
in a press release. “We’ve been keenly focused on ensur-
ing the importation approaches we’ve outlined pose no 
additional risk to the public’s health and safety. We know 
there are many operational challenges to address through 
each of these pathways, and are actively working through 
them as we look to formally announce these policies, with 
opportunity for public comment, in the coming months.”
The full action plan can be accessed via the HHS website 
at https://www.hhs.gov/sites/default/files/safe-importation-
action-plan.pdf. 
Pain Reliever Misuse Decreased by 11% 
in 2018, NSDUH Survey Indicates
Prescription drug misuse, including abuse of stimulants 
and pain relievers, decreased in 2018, according to the 
recently released 2018 National Survey on Drug Use and 
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USP Postpones Official Dates of USP 
General Chapters Revisions and Additions
United States Pharmacopeial Convention (USP) has 
announced that the effective date of the following changes 
to USP general chapters will be postponed:
♦  General Chapter <795> Pharmaceutical Compound-
ing – Nonsterile Preparations
♦  General Chapter <797> Pharmaceutical Compound-
ing – Sterile Preparations
♦  General Chapter <825> Radiopharmaceuticals – Prepa-
ration, Compounding, Dispensing, and Repackaging
The delay is in accordance with USP’s Bylaws, which 
require the official date of the standard to be postponed while 
an appeal is pending. In the meantime, conformance with the 
official versions of Chapters <795> and <797>, including 
the section “Radiopharmaceuticals as CSPs,” will remain 
official, according to a notice posted to the USP website.
Revisions to USP General Chapter <800> Hazardous 
Drugs – Handling in Healthcare Settings are not subject to 
pending appeals, and will become official on December 1, 
2019. During this interim period, Chapter <800> is “infor-
mational and not compendially applicable,” according to the 
USP notice. However, the organization encourages utiliza-
tion of the chapter in the interest of advancing public health. 
USP also notes that it plays no role in enforcement and that 
regulators continue to have the authority to make their own 
determinations regarding enforceability of Chapter <800>. 
FDA Issues Statement on Compounded 
Bulk Drug Substances Ruling
 A US district court judge in Washington, DC, recently 
upheld Food and Drug Administration’s (FDA’s) interpre-
tation of clinical need regarding bulk substances that may 
be used by outsourcing facilities in drug compounding. 
In response to the ruling, FDA has released a statement 
commending the decision as a “victory for public health 
in the first such case since the Drug Quality and Security 
Act (DQSA) was enacted.”
 In March 2019, FDA announced that vasopressin would 
not be included as an approved bulk drug substance because 
there is already an approved product on the market to meet 
the same medical needs. The ruling was in response to a 
challenge of that interpretation. In their statement, the 
agency states that they will continue to evaluate bulk drug 
substances nominated for use in compounding by outsourc-
ing facilities using the same interpretation of clinical need.
 “Our compounding work remains a top priority at the 
agency. We’ve long recognized that compounded drugs can 
serve an important role for patients whose medical needs 
cannot be met by an FDA-approved drug product,” the 
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Health (NSDUH). The annual survey, conducted by the 
Substance Abuse and Mental Health Services Administra-
tion (SAMHSA), a division of HHS, is a primary resource 
for data on mental health and substance use, including abuse 
of prescription drugs, among Americans. 
Key findings of the 2018 NSDUH include: 
♦ Past-year abuse of psycotherapeutics decreased from
6.6 from 6.2%.
♦ Past-year abuse of pain relievers decreased from 4.1%
to 3.6%.
♦ Past-year abuse of stimulants decreased from 2.1%
to 1.9%.
♦ Past-year abuse of opioids decreased from 4.2% to
3.7%.
“This year’s National Survey on Drug Use and Health 
contains very encouraging news: The number of Americans 
misusing pain relievers dropped substantially, and fewer 
young adults are abusing heroin and other substances,” 
said HHS Secretary Alex Azar. “At the same time, many 
challenges remain, with millions of Americans not receiv-
ing treatment they need for substance abuse and mental 
illness. Connecting Americans to evidence-based treatment, 
grounded in the best science we have, is and will remain 
a priority for President Donald Trump, for HHS, and for 
SAMHSA under Assistant Secretary Elinore McCance-
Katz.” 
A recorded presentation of the data, along with a written 
summary and the full report are available on the SAMHSA 
website at https://www.samhsa.gov/data/nsduh/reports-
detailed-tables-2018-NSDUH.
Additional Efforts Needed to Improve 
Naloxone Access, CDC Says 
A new Vital Signs report published by the Centers for 
Disease Control and Prevention (CDC) states that naloxone 
dispensing has grown dramatically since 2012, with rates 
of naloxone prescriptions dispensed more than doubling 
from 2017 to 2018 alone. However, the rate of naloxone 
dispensed per high-dose opioid dispensed remains low, 
with just one naloxone prescription dispensed for every 69 
high-dose opioid prescriptions.
The researchers for the report examined dispensing data 
from IQVIA, a health care, data science, and technology 
company that maintains information on prescriptions from 
50,400 retail pharmacies, representing 92% of all prescrip-
tions in the US. According to their analysis, dispensing rates 
were higher for female recipients than for male recipients, 
and higher for persons aged 60-64 years than for any other 
age group. The researchers also found that the rate of nal-
oxone prescriptions dispensed varied substantially across 
US counties, with rural and micropolitan counties more 
likely to have a low-dispensing rate.
 “Comprehensively addressing the opioid overdose epi-
demic will require efforts to improve naloxone access and 
distribution in tandem with efforts to prevent initiation of 
opioid misuse, improve opioid prescribing, implement harm 
reduction strategies, promote linkage to medications for 
opioid use disorder treatment, and enhance public health 
and public safety partnerships,” the report states in its con-
clusion. “Distribution of naloxone is a critical component of 
the public health response to the opioid overdose epidemic.”
The Vital Signs report can be accessed at www.cdc.gov/
mmwr/volumes/68/wr/mm6831e1.htm. 
Altaire Pharmaceuticals Recalls Multiple 
OTC Ophthalmic Products 
Due to a lack of sterility assurance, Altaire Pharma-
ceuticals, Inc, is voluntarily recalling over-the-counter 
(OTC) drug products and lots sold as generic ophthalmic 
medications at Walgreens, Walmart, CVS, and other retail 
pharmacies. To date, there have been no reports of adverse 
events related to the recalled products. 
A full list of the affected products and lot numbers, as 
well as instructions on how to return the product, are avail-
able through the following press releases: 
♦ Altaire Pharmaceuticals, Inc. Issues Voluntary Recall
Of Multiple Ophthalmic Products Sold At CVS
♦ Altaire Pharmaceuticals, Inc. Issues Voluntary Recall
of Multiple Ophthalmic Products Sold at Wal Mart
♦ Altaire Pharmaceuticals, Inc. Issues Voluntary Recall
of Multiple Ophthalmic Products Sold at Walgreens
♦ Altaire Pharmaceuticals, Inc. Issues Voluntary Recall
of Multiple Ophthalmic Products
Adverse reactions or quality problems experienced with 
the use of this product may be reported to FDA’s MedWatch 
Adverse Event Reporting program.
Pharmacists Invited to Participate in 
NAPLEX Pharmacy Practice Survey
The National Association of Boards of Pharmacy® 
(NABP®) sent email invitations to randomly-selected 
pharmacists in all areas of practice encouraging them to 
participate in the NAPLEX Pharmacy Practice Analysis 
Survey. Analysis of the survey results is used to evaluate 
the North American Pharmacist Licensure Examination® 
(NAPLEX®) competency statements.
The analysis of practice supports the relevance of the 
NAPLEX competency statements, which define the content 
for the examination. This analysis helps ensure that com-
petency statements, otherwise known as the examination 
“blueprint,” are in line with pharmacy practice standards 
and measure the knowledge, skills, and abilities of entry-
level pharmacists. In addition, the review supports the 
NABP mission to protect the public health by providing the 
state boards of pharmacy with a reliable means of assessing 
competency that assists them with licensure decisions to 
support safe and effective practice.
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2019, does not need to submit a petition for delayed 
compliance. A pharmacy is not eligible to receive 
delayed compliance for any non-compounding 
requirements in USP Chapter <800>.
 ♦ A compounding pharmacy that has been granted a 
delay in compliance will retain the delay as specified 
in the approval letter. The granted delay will be valid 
through the end date referenced in the approval letter. 
Electronic Prescribing Mandate –
January 1, 2020
In 2018, the Iowa Legislature passed legislation that will 
require all prescriptions, including controlled substances, to 
be electronically prescribed by prescribers and electronical-
ly received by pharmacies, beginning on January 1, 2020.
According to Surescripts data from September 2019, 
Iowa’s e-prescribing activity is still well below the 
national average. Of Iowa’s prescribers, 70.1% (versus 
76.5% nationally) are submitting electronic prescriptions 
to pharmacies. A total of 68.1% of Iowa’s prescribers 
have certified and audit-approved software that is capable 
of transmitting electronic prescriptions for controlled 
substances (EPCS). Yet, only 47.6% of Iowa’s prescribers 
have enabled this feature within their e-prescribing 
software (versus 41.3% nationally). 
Conversely, Iowa’s pharmacies are slightly above the 
national average for the ability to receive electronic pre-
scriptions (98.6% versus 98.4%, respectively) while the 
rate of EPCS-enabled pharmacies in Iowa hedges out the 
national averages by more than 2% (98.6% versus 95.9%, 
respectively).
The legislation requiring e-prescribing permitted several 
exceptions to the e-prescribing mandate. Prescriptions that 
are excluded from the mandate include:
1. A prescription for a patient residing in a nursing home, 
long-term care facility, correctional facility, or jail.
2. A prescription authorized by a licensed veterinarian.
3. A prescription dispensed by a US Department of 
Veterans Affairs pharmacy.
4. A prescription requiring information that makes elec-
tronic submission impractical, such as complicated or 
lengthy directions for use or attachments.
5. A prescription for a compounded preparation contain-
ing two or more components.
6. A prescription issued in response to a public health 
emergency in a situation where a non-patient-specific 
prescription would be permitted.
7. A prescription issued pursuant to an established and 
valid collaborative practice agreement, standing order, 
or drug research protocol.
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8. A prescription issued during a temporary technical or 
electronic failure at the practitioner’s or pharmacy’s 
location, provided that a prescription issued pursuant 
to this subparagraph shall indicate on the prescription 
that the practitioner or pharmacy is experiencing a 
temporary technical or electronic failure.
9. A prescription issued in an emergency situation pur-
suant to federal law and regulation rules of the Board.
Additionally, a practitioner, medical group, or pharmacy 
that is unable to timely comply with the electronic 
prescribing requirements may petition the Board for 
an exemption based on economic hardship; technical 
limitations that the practitioner, medical group, or pharmacy 
cannot control; or other exceptional circumstances. The 
Board may grant exception requests for a period of time 
that may not exceed one year, which may be renewable with 
Board approval. Exemption petition forms and additional 
information regarding the e-prescribing mandate can be 
found on the Board’s website.
After the mandate becomes effective on January 1, 
2020, a pharmacist who receives a written, oral, or faxed 
prescription that is otherwise legitimate will not be 
required to verify that the prescription is subject to an 
exception listed above and may dispense the prescription. 
However, a pharmacist must exercise professional judgment 
in identifying and reporting suspected violations of the 
e-prescribing mandate to either the Board or the appropriate 
professional licensing board of the practitioner. 
A prescriber who violates this mandate is subject to 
an administrative penalty of $250 per violation, up to a 
maximum of  $5,000 per calendar year. The administrative 
penalty assessed by the prescriber’s primary licensing board 
will not be considered a disciplinary action or reported as 
discipline. A practitioner may appeal the assessment of 
the administrative penalty, which will initiate a contested 
case proceeding. The administrative penalties collected 
will be deposited into the drug information program fund 
to further support and enhance the state’s prescription 
monitoring program.
Statewide Protocols
The Board’s statewide protocols for naloxone, nicotine 
replacement products, and immunizations went into 
effect on April 5, 2019. Pharmacists acting under the 
statewide protocol may need to obtain a national provider 
identification (NPI) number in order to properly bill the 
prescriptions to third-party payers. 
Additionally, the Iowa Legislature postponed the 
sunsetting of the physician-approved immunization 
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protocols from July 1, 2019, to July 1, 2020. The legislature 
recognized that additional time may be necessary to ensure 
that Iowa Medicaid recognizes the pharmacists’ NPI 
number on the claims being submitted for immunizations 
under the statewide protocol. 
Technician Product Verification 
Programs
The Board adopted final rulemaking to rescind 
Chapter  40, “Tech-Check-Tech Programs” and adopt 
the new Chapter 40, “Technology-Assisted Technician 
Product Verification Programs.” During the 2018 session 
of  the Iowa Legislature, the IAC was amended to allow 
technician product verification (TPV) programs in 
community pharmacies. Previous programs were called 
tech-check-tech programs and only authorized the practice 
in a hospital pharmacy or community pharmacy providing 
care for facility patients when another licensed health care 
practitioner would be administering the medications. Under 
the new rules, which became effective June 26, 2019, a 
pharmacy may establish a TPV program that is intended to 
redirect pharmacist time to increased clinical services (such 
as medication therapy management, collaborative practice, 
statewide protocols, and immunizations). In a pharmacy 
using a TPV program, pharmacist hours shall not be 
reduced but shall be redistributed to clinical pharmacy 
services to improve patient care and health outcomes.
Additional TPV program requirements include:
 ♦ appropriate scanning technology to ensure that each 
product is accurately filled and verified
 ♦ no more than three checking technicians per 
pharmacist involved in the prescription-filling process 
(institutional settings are exempt)
 ♦ advance notice to the Board of program implementation
 ♦ minimum qualifications for checking technicians
 ♦ quality assurance process
◊ quarterly verification
◊ quarterly reports
 ♦ record keeping
The Board did not authorize “grandfathering” of 
any previously existing tech-check-tech programs, so 
pharmacies are expected to be compliant with the revised 
rules in Chapter 40, unless the pharmacy has received a 
waiver. The complete chapter is available on the Board’s 
website.
Want to Know What Rules Are 
Changing?
The Board establishes the minimum standards for the 
practice of pharmacy and lays out those standards in rules. 
Changes to rules are initiated by a variety of triggers:
 ♦ legislation or legislative mandates
 ♦ overall review of rules, required every five years
 ♦ a suggestion from a licensee, compliance staff 
member, or stakeholder
 ♦ following the receipt of a number of waivers to a rule
The Board encourages all licensees and registrants 
to be aware of rulemaking undertaken by the Board 
and appreciates licensee participation through the open 
comment opportunities.
Throughout the rulemaking process, each rulemaking 
is available for review by interested individuals. When the 
Board is considering rulemaking, the documents to be voted 
on are available on the Board’s website. From the home 
page, select “Board,” then “Meetings,” then the meeting 
date of interest, and scroll to the bottom of the page for 
the “Meeting Materials” section where all the proposed 
rulemaking documents will be attached. 
Following approval from the full Board on a rulemaking, 
the rules are filed and published in the Iowa Administrative 
Bulletin. This is published every two weeks and includes all 
rulemaking in Iowa. Rulemaking filings can also be found 
at rules.iowa.gov. Another resource for reviewing all the 
rulemaking underway by the Board is the Rules Tracker. 
On this site, choose to search rulemakings by “Agency.” 
In the “Select an Agency” drop-down list, scroll down to 
“Public Health Department,” under which you should select 
“Pharmacy Board” to view a list of rulemaking documents. 
Finally, the Board recommends subscribing to its email 
distribution list to receive notice when rulemaking is 
approved. You can sign up for this from the Board’s home 
page in the “Social Media” area.
